Atrial fibrillation and heart failure comorbidity

Area of Science:

• Cardiology
• Internal Medicine

Background:

• Atrial fibrillation (AF) and heart failure (HF) commonly affect older patients with shared cardiac conditions.
• AF prevalence in HF ranges from 10% to 30%, with conflicting data on its independent impact on mortality.
• Optimal HF management can influence AF outcomes and survival.

Purpose of the Study:

• To outline key management strategies for AF in HF patients.
• To evaluate the roles of rate control, rhythm control, anticoagulation, and sudden cardiac death prevention.

Main Methods:

• Review of existing data and randomized trials on AF management in HF.
• Discussion of pharmacological and non-pharmacological treatment options.
• Emphasis on individualized treatment decisions based on patient status.

Main Results:

• Long-term oral anticoagulation is recommended for HF patients with AF.
• Rhythm control for survival benefit is not currently justified due to safety and efficacy uncertainties.
• Rate control is an acceptable strategy, often improving left ventricular function.
• Amiodarone is a preferred agent for rhythm and rate control.
• Catheter ablation and defibrillator implantation are effective non-pharmacological options.

Conclusions:

• Management hinges on optimal HF care, anticoagulation, and tailored rate/rhythm control.
• Rhythm control is primarily for symptom management, not survival.
• Rate control, particularly with AV node blockade and beta-blockers, is effective.
• Advanced therapies like ablation and defibrillators play crucial roles.